### INDEX

- **Injury (Cont.)**
  - vesical, 11
  - urethral, 77
- Instrumentation, 34-37, 83
- Intensity-modulated radiation therapy, See IMRT
- Invasive interventional techniques, 1-5, 5-7, 7-8
- Intraductal coagulation tumor necrosis, 69
- Jets, 90-91
- Kidney, 118
  - clinical staging, 118–119
  - diffusion-weighted imaging, 123
  - dynamic-contrast imaging, 123–124
  - MR technique, 119–120
  - recurrence, 123
  - stage, 122–123
  - tumor localization, 120–122
- Kidney cancer, 70, 146–149, 167
  - initial diagnosis and staging, 167
- Kupffer cells, 103, 105
- Laparoscopic, 1, 3, 5, 45, 64, 70, 74, 79, 80, 95, 98
- Light delivery systems, 98
- Liposomes, 106, 110–111
- Lower urinary tract symptoms (LUTS), 82
- Lesions, 91
  - homogenous, 98
- Lymph node metastases, 119, 123, 133, 155–156, 158, 160
- Lymph nodes, 109, 123, 126, 133, 158, 160
- Magnetic resonance imaging (MRI), 6, 17, 23, 31, 36, 44, 67, 68, 71
  - multiparametric, 6, 128–129, 194, 196, 202
- scan, 3-4
- Schematic representation of, 171
- Thrombectomy, 36
- Memorial Sloan-Kettering Cancer Center, 10
- Mobile organs, 36
- Nanomaterials
  - enhanced permeability and retention effect, 105-106
  - for cancer therapy, 109-113
  - immune system, 107-108
  - nanoparticles-based vaccines
  - liposomes, 109
  - nondegradable nanoparticles, 108-109
  - size and interactions with organs, 103-104
  - surface physicochemical characteristics, 107
- Nanomedicine, 102
- Nanoparticle vaccines, 106-109
- Nanotechnology
  - perspectives on, 102–113
  - biodistribution of nanomaterials, 102–103
- Necrosis: imaging protocol, 184–185
- Needle, periurethral, 21
- Nephrogenic systemic fibrosis (NSF), 123
- Nephron-sparing techniques, 79–81
- Nonseminomatous germ cell tumors, 168–169
- NSF, See Nephrogenic systemic fibrosis
- Nucleic acid delivery, 112–113
- Palladium bacteriopheophorbides
  - WST-09, 90
  - WST-11, 90
- PEGylation, 106–107
- Penile cancer, 160–162
- Phenanthroperylenquinone derivative, Hypericin, 90
- Photodynamic therapy
  - comparison of clinical studies, 96–97
  - light sources, 90–91
  - definition, 87
  - diagnosis, 86
  - history, 87
  - Photosensitization, 87
  - Photosensitizing drugs
    - 5-amino levulinic acid, 89
    - chlorins, 88-89
    - phthalocyanines, 89
  - Phototoxicity, 87
  - poly(lactic-coglycolic acid) (PLGA), 108
  - Polymers, 111-112
  - Positron emission tomography, 160-161
  - Prostate, 26
- Prostate adenocarcinoma, 82
- contrast-enhanced MR imaging, 130
- conventional TRUS of, 143
- diffusion-weighted imaging, 127
- MR-guided biopsy, 130–131
- proton MR spectroscopic imaging, 127–129
- T2-weighted imaging, 126-127
- TRUS biopsy of, 122
- Prostate cancer, 157–158, 183-194
- prostate MR spectroscopic imaging, 127–129
- recurrence, 81
- screening, 65
- PSA, See Prostate-specific antigen
- Radiation therapy, 44
- Radiation Therapy Oncology Group (RTOG), 25
- Radiofrequency ablation, 2, 64
  - classification of, 78
  - comparisons with nephron-sparing techniques, 79–81
- electrons, 69, 78–77
- lesions, 81
- Radionuclides, 161–162
- RCC, See Renal cell carcinoma
- Renal cancer, 95-98
- photodynamic diagnosis, 95
- Renal cell carcinoma (RCC), 68, 70, 72, 77, 78, 81–82
- rectums, 79, 81
- Renal lesions, 181
- Renal tumor, small T1 postcontrast subtraction images of, 182
- RFA electrodes, 69
- RNA interference (RNAi) pathway, 113
- Robinson catheter, 20
- Sacrum and bones, 131–133
- clinical staging, 35
- MR imaging, 153–154
- MR technique, 135
- Seminomatous germ cell tumors, 149-170
- Spectroscopy, 126, 133, 185, 192, 194
- Society of Interventional Radiology, 78–79
- Superoxide radicals, 88-89
- Technique
  - operative
  - patient Selection, 52–53
- Testicular cancer, 159–159
- Testis et al, see Para-aortic (ParaT2), 90
- Toxicity, 25–26
- Transitional cell cancer, 155-156
- Transrectal ultrasonic (TRUS), 17-18
- 20 guidance, 82
- images, 82
  - monitoring, 80
- ultrasound, 14
- Transurethral resection, 23
- Tumors
  - bladder, 45-46
  - CF images of
  - exophytic, 71
  - renal tumors, 71
  - necrosis, 34, 65, 123, 134
  - rectal, 48-49
  - teratoma, 46-47
  - transitional, 159

---

198
### INDEX

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrasonography</td>
<td>34–38, 43, 46, 142</td>
</tr>
<tr>
<td>technical advances in</td>
<td>142</td>
</tr>
<tr>
<td>Ultrasonic</td>
<td>141</td>
</tr>
<tr>
<td>contrast-enhanced</td>
<td>142–143, 145–146</td>
</tr>
<tr>
<td>cryosurgery</td>
<td>17</td>
</tr>
<tr>
<td>demonstration for</td>
<td>181</td>
</tr>
<tr>
<td>Doppler</td>
<td>181</td>
</tr>
<tr>
<td>image seed</td>
<td>22</td>
</tr>
<tr>
<td>monitoring</td>
<td>53</td>
</tr>
<tr>
<td>scrotal</td>
<td>46</td>
</tr>
<tr>
<td>waves</td>
<td>21</td>
</tr>
<tr>
<td>Urethral Foley catheter</td>
<td>57</td>
</tr>
<tr>
<td>Urethral warming catheter</td>
<td>57</td>
</tr>
<tr>
<td>Urologic cancer</td>
<td>17</td>
</tr>
<tr>
<td>diagnosis and staging of</td>
<td>14, 25, 36</td>
</tr>
<tr>
<td>Urotherapy</td>
<td>14, 25, 36</td>
</tr>
<tr>
<td>Vaccines</td>
<td>113</td>
</tr>
<tr>
<td>nondegradable nanoparticle</td>
<td>108–109</td>
</tr>
<tr>
<td>Vascular endothelial growth factor (VEGF)</td>
<td>81–82</td>
</tr>
<tr>
<td>receptor</td>
<td>81–82</td>
</tr>
<tr>
<td>Visualization, urethral</td>
<td>22</td>
</tr>
<tr>
<td>Wavelength</td>
<td>86, 89, 90, 92, 96</td>
</tr>
<tr>
<td>White light cystoscopy</td>
<td>91</td>
</tr>
<tr>
<td>Whole-gland radical treatments</td>
<td>5</td>
</tr>
<tr>
<td>Whole-gland ablation</td>
<td>55, 61</td>
</tr>
<tr>
<td>Whole-gland cryotherapy</td>
<td>4, 57, 61–62</td>
</tr>
<tr>
<td>WST-09, 90</td>
<td></td>
</tr>
<tr>
<td>Zeta, 105</td>
<td></td>
</tr>
</tbody>
</table>